Nutraceutical Support With Omega-3

• Status: Completed
• Trial end date: 2017-03-15
• Target enrollment: 0
• Participant gender: All

Summary

Although evidence have clearly proved that intravitreal injection of vascular endothelial growth factor antagonists prevents vision loss and may even improve visual acuity in patients with neovascular AMD, a significant percentage of patients continue to lose visual acuity. Moreover, monthly intravitreal injections represent a burden for society as well as the caregiver.

Combination therapy with either topical 0.1% pranoprofen or nutraceutical support with AREDS2 formula plus omega-3 might act synergistically with intravitreal injection, offering valuable therapeutic support to aflibercept injections in patients requiring long-term treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Università degli Studi di Brescia
• Treatments: Aflibercept; Carotenoids; Pyranoprofen

Criteria

Inclusion Criteria:

• provision of written informed consent and compliance with study assessments for the full duration of the study

• age > 40 years

• presence of treatment-naïve neovascular AMD

Exclusion Criteria:

• any previous intravitreal treatment

• previous laser treatment in the study eye

• myopia > 7 diopters in the study eye

• concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy and advanced glaucoma)

• concurrent corneal epithelial disruption or any condition that would affect the ability of the cornea to heal

• known sensitivity to any component of the formulations being investigated.